[go: up one dir, main page]

WO1998006410A1 - Composition contenant du zinc - Google Patents

Composition contenant du zinc Download PDF

Info

Publication number
WO1998006410A1
WO1998006410A1 PCT/JP1997/002770 JP9702770W WO9806410A1 WO 1998006410 A1 WO1998006410 A1 WO 1998006410A1 JP 9702770 W JP9702770 W JP 9702770W WO 9806410 A1 WO9806410 A1 WO 9806410A1
Authority
WO
WIPO (PCT)
Prior art keywords
zinc
vitamin
containing composition
concentration
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1997/002770
Other languages
English (en)
Japanese (ja)
Inventor
Kazuo Hasegawa
Takako Ishii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to AU37842/97A priority Critical patent/AU3784297A/en
Publication of WO1998006410A1 publication Critical patent/WO1998006410A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Definitions

  • the present invention relates to a zinc-containing composition in which the risk of occurrence of excess zinc is reduced, and is applied to the fields of medicine, food, and the like.
  • Zinc is contained in all tissues and body fluids of humans and is the second highest-content trace element after iron.
  • Trace elements are essential elements for living organisms that require a daily intake of 100 mg or less, and there are 15 types of substances other than zinc, such as iron and copper.
  • Physiological effects of zinc include growth * skeletal development, activation of skin and its attached organs, maintenance of reproductive function, maintenance of taste and smell, effects on spirit and behavior, increased immune function, etc. can give.
  • An object of the present invention is to provide a highly safe zinc-containing composition in which the side effect of zinc due to excessive lead removal is reduced without impairing the physiological action of zinc. Disclosure of the invention
  • the present inventors have conducted intensive studies in order to reduce the side effects caused by excessive intake of zinc. As a result, by combining vitamin B and zinc with a certain ratio, the physiological effects of zinc can be reduced. In particular, they have found that zinc excess can be prevented and zinc deficiency can be improved without impairing the skin beautiful effect of zinc, and the present invention has been completed.
  • the present invention consists of vitamins and zinc-containing component, the proportion of zinc of vitamin B 6 compound and zinc-containing component is 0.5 5: and characterized by a 1 molar ratio: 1 to 2.2 Is a zinc-containing composition.
  • the effective dose of zinc is 1 to 50 mg per mouth, preferably 5 to 2 O mg for an adult.
  • the effective projecting amount of vitamin B 6 such daily adult for zinc, the molar ratio 0.5 5: 1 to 2.2: 1, preferably 0.7 6: 1-2. 2: 1. If the zinc excess is used and the molar ratio of vitamin B 6 to zinc is out of this range, the skin overgrowth caused by the zinc excess is deteriorated.
  • the zinc-containing component in the present invention is a salt containing zinc, and any salt of an organic ion or an inorganic ion may be used as long as the anion is non-toxic.
  • organic ion for example,?
  • examples of ions of organic acids such as citrate, gluconic acid, cunic acid, malic acid, and tartaric acid
  • examples of inorganic ions include ions of sulfuric acid, carbonic acid, chloride, phosphoric acid, and nitric acid. That is, examples of the zinc-containing component in the present invention include zinc dalconate, zinc quenate, zinc sulfate, zinc carbonate, zinc chloride, and zinc phosphate, with zinc gluconate and zinc sulfate being particularly preferred.
  • These salts may be anhydrous or hydrated.
  • the vitamin B 6 such as, for example, pyridinium Dokishin, pyridinium Dokisaru, pyridinium Dokisa Examples thereof include mine, pyridoxine phosphate, pyridoxal phosphate, pyridoxamine phosphate, and salts thereof. One or more of these vitamin B6s can be used.
  • the zinc-containing composition of the present invention may contain other vitamins, for example, vitamin B group, vitamin C, vitamin A, vitamin D, vitamin E, and the like. One or more of these vitamins can be used.
  • the zinc-containing composition of the present invention may contain other minerals, for example, salts such as iron, copper, magnesium, and calcium. One or more of these minerals can be used.
  • Crude drugs, crude drug extracts and the like can be blended as other medicinal ingredients.
  • the zinc-containing composition of the present invention may be used as it is or as necessary with other known additives such as a shaping agent, a disintegrant, a binder, a lubricant, an antioxidant, a coating agent, a coloring agent, and a fragrance.
  • a shaping agent such as a silicone, a silicone, a styrene, a styrene, a styrene, a sulfate, sorbiol, sorbiol, sorbiol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol
  • Vitamin C calcium 1 80 mg
  • the resulting mixed powder was filled into soft capsules or soft capsules at 560 mg each to obtain four force busel agents.
  • mice Ten kinds of experimental diets having the compositions shown in Table 1 were prepared by a conventional method.
  • the zinc concentration was set to 2 mg for normal diet, 100 g for deficient diet, 0.3 mg / 100 g for deficient diet, and 6 mg for excess diet, and 100 g for 100 mg of vitamin.
  • pyridoxine hydrochloride was used for vitamins. 0.4 mg
  • the 4-week-old male hairless rats were divided into 10 groups, and each group consisted of 8 animals. Each animal was bred for 4 weeks on 10 different diets (N 0.1 to 10), and the transepidermal water loss (TE WL) (No.
  • T EWL transepidermal water loss
  • red blood cells were separated and washed from heparin blood collected from the inferior vena cava, lysed with water, hemoglobin was removed with ethanol / chloroform, water-ethanol layer was removed, water was added, and test samples (blood conversion) In 1/1000 dilution, The final ethanol content was 0.25%).
  • Reagent A substrate solution: 0.2 ml (0.2 mM hydroxyxamine, 0.2 mM hypoxanthine, plI 7.0) 0.5 ml (water the KC NZ final concentration of 1 mM), reagent B (reaction start solution): 0. 2 ml (1. 2 5 mU Kisanchi Nokishide Ichisu, 1 0- 4 MED TA- 2 N a), buffer: 0.
  • the TEWL value is low at a zinc concentration of 2 mg / 100 g and a zinc-deficient diet (zinc concentration 0%). 3 mg Z l 0 0 g) causes a worsening of skin conditions due to zinc deficiency, and a zinc overdose (zinc concentration 6 mg Z 100 g) causes a worsening of skin conditions due to excess zinc, and zinc ingestion The dosage range was very narrow. If only zinc is administered to remedy zinc deficiency, the risk of subhyperplasia is very high. Table 2 Effect of dietary zinc concentration on transepidermal water loss (TEWL)
  • TEWL values are indicated by average soil SEM 2 From Table 3, it can be seen from Table 3 that when the zinc concentration of 6 mgZ, which causes hyperzincism, is 100 g, the molar ratio of vitamin B fi to the zinc amount is 0.55: 1 to 2.2: 1. At (No. 4 to 8), the TEWL value was the normal control value (No. 2), and no zinc excess occurred.
  • Zinc hyperkinesia against zinc content the amount of vitamin B beta zinc concentration of normal 2 m gZ 1 0 0 g to not cause, 1. molar ratio 00:. 1 if (N o 1 At 0), the TEWL value was not different from the normal control value (No. 2) fed on a normal diet, and even at the optimum zinc concentration, increasing vitamin Be did not adversely affect zinc absorption.
  • Table 3 Transepidermal water root loss (TEWL) for zinc and vitamin B concentrations
  • a highly safe zinc-containing composition in which side effects of zinc due to excessive intake of zinc are reduced without impairing the physiological action of zinc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une composition contenant du zinc comprenant de la vitamine B6 et un constituant zincifère se caractérise en ce que le rapport molaire entre la vitamine B6 et le zinc contenus dans le constituant se situe entre 0,55:1 et 2,2:1. Cette composition présente des effets secondaires réduits du fait de l'apport excessif de zinc et elle présente par conséquent une excellente sécurité.
PCT/JP1997/002770 1996-08-12 1997-08-07 Composition contenant du zinc Ceased WO1998006410A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37842/97A AU3784297A (en) 1996-08-12 1997-08-07 Zinc-containing composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8/212604 1996-08-12
JP21260496 1996-08-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/006,358 Continuation-In-Part US6007243A (en) 1996-02-21 1998-01-13 Combined mobile x-ray imaging system and monitor cart

Publications (1)

Publication Number Publication Date
WO1998006410A1 true WO1998006410A1 (fr) 1998-02-19

Family

ID=16625451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/002770 Ceased WO1998006410A1 (fr) 1996-08-12 1997-08-07 Composition contenant du zinc

Country Status (2)

Country Link
AU (1) AU3784297A (fr)
WO (1) WO1998006410A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5338630A (en) * 1976-09-17 1978-04-08 Riishiyu Pharm Corp Composition comprising zinc based composite vitamins and mineral
JPS5782318A (en) * 1980-09-19 1982-05-22 Garufuinkeru Doron Novel drug composition containing zinc salt
JPS6317831A (ja) * 1986-05-27 1988-01-25 ロ−ラ−　インタ−ナシヨナル　オ−バ−シ−ズ　インコ−ポレ−テツド マルチビタミン／微量元素調合物の安定化
JPH01500745A (ja) * 1983-05-03 1989-03-16 エス．エス．エム．インターナショナル　ケミカル　カンパニー　リミテッド 注射可能なビタミン組成物
JPH04346770A (ja) * 1990-10-26 1992-12-02 Maurizio Luca 栄養補給組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5338630A (en) * 1976-09-17 1978-04-08 Riishiyu Pharm Corp Composition comprising zinc based composite vitamins and mineral
JPS5782318A (en) * 1980-09-19 1982-05-22 Garufuinkeru Doron Novel drug composition containing zinc salt
JPH01500745A (ja) * 1983-05-03 1989-03-16 エス．エス．エム．インターナショナル　ケミカル　カンパニー　リミテッド 注射可能なビタミン組成物
JPS6317831A (ja) * 1986-05-27 1988-01-25 ロ−ラ−　インタ−ナシヨナル　オ−バ−シ−ズ　インコ−ポレ−テツド マルチビタミン／微量元素調合物の安定化
JPH04346770A (ja) * 1990-10-26 1992-12-02 Maurizio Luca 栄養補給組成物

Also Published As

Publication number Publication date
AU3784297A (en) 1998-03-06

Similar Documents

Publication Publication Date Title
DE69710557T2 (de) Zinc, Kupferverbindung und Aminosäure enthaltende Zusammensetzung zur oralen Verabreichung
DE3587766T2 (de) Verbesserungen am geschmack von zinkzusätzen für orale verwendung.
US8182850B2 (en) Mixture of iron and copper salts masking metallic taste
US6818228B1 (en) Dietary supplements containing ultradense calcium citrate and carbonyl iron
EP2073821B1 (fr) Mélange de sels de fer et de cuivre masquant un goût métallique
JP2904788B2 (ja) 高い生物学的利用能をもつ鉄‐カルシウムミネラル補給物
WO1994008472A1 (fr) Source de calcium biodisponible concentre
USRE33988E (en) Dietary supplementation with essential metal picolinates
KR20110128329A (ko) 인산염 흡착제
NZ249396A (en) Nutritional product containing selenate
CN103404594A (zh) 一种具有促进排铅作用的功能性乳品及其制备方法
DE69906651T2 (de) Zusammensetzungen mit langsamer Freigabe enthaltend eine Zinkverbindung und Vitamin C-Derivate
WO2012099304A1 (fr) Procédé pour la préparation de solution aqueuse de phosphate de calcium à haute concentration stable à l'état neutre
MXPA02003459A (es) Complejos de cromo-histidina como complementos nutricionales.
JP3484689B2 (ja) 微量元素製剤
CN1116925A (zh) 鱼肝油乳及其制备方法
WO1998006410A1 (fr) Composition contenant du zinc
JPH10109940A (ja) 亜鉛含有組成物
US5665385A (en) Dietary metal supplements
EP1675598B1 (fr) Composition d'oligo-elements destines a l'alimentation
Sørensen et al. Effects of diethyldithiocarbamate and tetraethylthiuram disulfide on zinc metabolism in mice
WO2008001110A2 (fr) Compositions de manganèse, zinc et sélénium, leurs préparations et leurs utilisations
CN109043547A (zh) 一种螯合铁多维营养粉及其制备方法
US20230158066A1 (en) Encapsulated carbonyl iron salt compositions and process thereof
ZA200607591B (en) Rapidly disintegrating taste-masked tablet

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA